IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients – a cohort study
Gaya Spolverato(University of Padua), Salvatore Pucciarelli(Azienda Ospedale - Università Padova), Silvio Guerriero, Giulia Capelli(University of Padua), Roberta Salmaso, Giulia Becherucci(University of Padua), Ignazio Castagliuolo(University of Padua), Maurizio Zizzo(Azienda Sanitaria Unità Locale di Reggio Emilia), Chiara Cipollari(La Salle University), Ivana Cataldo(Ospedale SS. Annunziata), Giuseppe Portale(University of Southern California), Angelo Paolo Dei Tos(University of Padua), Francesca Bergamo(Istituto Oncologico Veneto), Cesare Ruffolo(Ca' Foncello Hospital), Astghik Stepanyan(University of Padua), Vittorina Zagonel(Istituto Oncologico Veneto), Marco Massani(AULSS 2 Marca Trevigiana), Silvia Negro(University of Padua), Stefano Brignola(University of Padua), Valentina Chiminazzo(University of Padua), Roberto Merenda(Ospedale Civile di Venezia), Tommaso Stecca(Ca' Foncello Hospital), Giorgio Rivella(University of Padua), Antonio Scapinello(Istituto Oncologico Veneto), Matteo Fassan(University of Padua), Luca Dal Santo(University of Padua), Romeo Bardini(University of Padua), Michela Campi(Ca' Foncello Hospital), Pierluigi Pilati(Istituto Oncologico Veneto), Francesco Cavallin, Marco Agostini(University of Padua), Chiara Romiti, Gianluca Businello(University of Padua), Federico Scognamiglio(University of Padua), Andromachi Kotsafti(Istituto Oncologico Veneto), Luca Facci(University of Padua), Ottavia De Simoni(Istituto Oncologico Veneto), Giovanni Pirozzolo(Ottawa Hospital), Barbara Di Camillo(University of Padua), Alfonso Recordare(Ca' Foncello Hospital), Imerio Angriman, Boris Franzato(Istituto Oncologico Veneto), Giovanni Bordignon(AULSS 2 Marca Trevigiana), Chiara Vignotto(University of Padua), Isacco Maretto(University of Padua), Vincenza Guzzardo(University of Padua), Andrea Porzionato(University of Padua), Anna Pozza(University of Padua), Francesco Marchegiani
Cited by 11
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k